DIG
LYEL icon

Dragoneer Investment Group’s Lyell Immunopharma LYEL Stock Holding History

Dragoneer Investment Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$14.8M – 75
2021
Q3 		$14.8M Hold
50,000
– – 0.19% 50
2021
Q2 		$16.2M Buy
+50,000
New +$16.4M 0.21% 50

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Dragoneer Investment Group's LYEL Position: Q4 2021 in Review

Dragoneer Investment Group sold out of Lyell Immunopharma (LYEL) in Q4 2021, closing a stake of 50,000 shares — an estimated $14.8M sold.

Dragoneer Investment Group first reported a position in LYEL in Q2 2021 and held it in 2 quarters. The position peaked at $16.2M in Q2 2021. 77 funds tracked by Wall St. Rank hold LYEL as of Q4 2021.

  • Dragoneer Investment Group reported no remaining Lyell Immunopharma position as of Q4 2021 after selling out during the quarter.
  • Dragoneer Investment Group sold 50,000 Lyell Immunopharma shares in Q4 2021, an estimated $14.8M.
  • Dragoneer Investment Group first reported a position in Lyell Immunopharma in Q2 2021 and held it in 2 quarters.
  • Dragoneer Investment Group's Lyell Immunopharma position peaked at $16.2M in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2021.

Based on Dragoneer Investment Group's 13F filing for Q4 2021, filed 15 Feb 2022.